2seventy bio, Inc. announced that upon closing of the transaction with Regeneron, the newly formed 2seventy bio leadership team will also include Vicki Eatwell, currently senior vice president of finance, who will become chief financial officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.3 USD | +2.87% | +0.70% | +0.70% |
08/05 | Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, vs. Street Est of $14.1M | MT |
08/05 | Transcript : 2seventy bio, Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.70% | 221M | |
+46.19% | 55.7B | |
-6.14% | 39.57B | |
+39.19% | 39.91B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
-0.35% | 12.12B | |
+24.18% | 12.12B | |
+28.38% | 12.17B |
- Stock Market
- Equities
- TSVT Stock
- News 2seventy bio, Inc.
- 2seventy bio, Inc. Appoints Vicki Eatwell as Chief Financial Officer